Form PTO-1449 U.S. Department of Commerce Patent & Trademark Office	Atty. Docket No. 1064/48505	Serial No. 09/761,636
INFORMATION DISCLOSURE STATEMENT *(Use several sheets if necessary)*	Applicants Marc G. ACHEW, et al	
	Filing Date January 18, 2001	Group 1644

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date (if appropriate)
PNH	AA	5,932,540	08/1999	HU, et al.			
	AB	5,935,820	08/1999	Hu, et al.			

FOREIGN PATENT DOCUMENTS

		Document	Date	Country	Class	Sub-class	Translation Yes | No
PNH	AC	WO9807832	02/1998	WO			Yes

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

PNH	AD	Arja KAIPAINEN, "Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development" Proc. Natl. Acad. Sci, USA, April 1995 Vol 92: 3566-70.
	AE	James LEE, "Vascular endothelial growth factor-related protein: A ligand and specific activator of the tyrosine kinase receptor Flt4" Proc. Natl. Acad. Sci, USA, March 1996 Vol 93: 1988-92.
	AF	J. TAIPALE, "Vascular Endothelial Growth Factor Receptor-3" Current Topics in Microbiology and Immunology, Vol. 237, 1999 Vol 237: 85-96.
	AG	Arja KAIPAINEN, "Enhanced Expression of the Tie Receptor Tyrosine Kinase Messenger RNA in the Vascular Endothelium of Metastatic Melanomas" Cancer Research, December 1994 Vol 54: 6571-77.
	AH	Vladimir JOUKOV, "A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases" The EMBO Journal, 1996 Vol 15(2): 290-298.
	AI	Marc G. ACHEN, "Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3" Eur. J. Biochemistry, February 2000 Vol 267: 2505-15.
	AJ	Marc G. ACHEN, "Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)" Proc. National Acad. of Science, January 1998 Vol 95: 548-553.
✓	AK	Steven STACKER, "VEGF-D promotes the metastatic spread of tumor cells via the lymphatics" Nature Medicine, February 2001 Vol 7(2): 186-191.

EXAMINER	DATE CONSIDERED 6/17/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.